vs
Embecta Corp.（EMBC）与UiPath, Inc.（PATH）财务数据对比。点击上方公司名可切换其他公司
UiPath, Inc.的季度营收约是Embecta Corp.的1.6倍（$411.1M vs $261.2M），UiPath, Inc.净利率更高（48.4% vs 16.9%，领先31.5%），UiPath, Inc.同比增速更快（15.9% vs -0.3%），UiPath, Inc.自由现金流更多（$25.1M vs $16.6M），过去两年UiPath, Inc.的营收复合增速更高（0.7% vs -4.6%）
Embecta Corp.是一家专注于糖尿病护理领域的全球医疗科技企业，主要设计、生产及销售胰岛素笔针、注射器、输注组件等给药装置，产品服务覆盖全球多个地区的患者、医疗机构及生物制药合作方。
UiPath是一家全球化软件企业，专注于开发人工智能、智能自动化及流程编排类软件，其产品支持用户搭建与调度AI代理，实现复杂业务流程、工作流的自动化运行，助力各行业客户提升运营效率、降低人力成本。
EMBC vs PATH — 直观对比
营收规模更大
PATH
是对方的1.6倍
$261.2M
营收增速更快
PATH
高出16.2%
-0.3%
净利率更高
PATH
高出31.5%
16.9%
自由现金流更多
PATH
多$8.5M
$16.6M
两年增速更快
PATH
近两年复合增速
-4.6%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $261.2M | $411.1M |
| 净利润 | $44.1M | $198.8M |
| 毛利率 | 61.9% | 83.3% |
| 营业利润率 | 31.9% | 3.2% |
| 净利率 | 16.9% | 48.4% |
| 营收同比 | -0.3% | 15.9% |
| 净利润同比 | — | 1966.2% |
| 每股收益（稀释后） | $0.74 | $0.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EMBCPATH
| Q4 25 | $261.2M | $411.1M | ||
| Q3 25 | $264.0M | $361.7M | ||
| Q2 25 | $295.5M | $356.6M | ||
| Q1 25 | $259.0M | $423.6M | ||
| Q4 24 | $261.9M | $354.7M | ||
| Q3 24 | $286.1M | $316.3M | ||
| Q2 24 | $272.5M | $335.1M | ||
| Q1 24 | $287.2M | $405.3M |
净利润EMBCPATH
| Q4 25 | $44.1M | $198.8M | ||
| Q3 25 | $26.4M | $1.6M | ||
| Q2 25 | $45.5M | $-22.6M | ||
| Q1 25 | $23.5M | $51.8M | ||
| Q4 24 | $0 | $-10.7M | ||
| Q3 24 | $14.6M | $-86.1M | ||
| Q2 24 | $14.7M | $-28.7M | ||
| Q1 24 | $28.9M | $33.9M |
毛利率EMBCPATH
| Q4 25 | 61.9% | 83.3% | ||
| Q3 25 | 60.0% | 82.2% | ||
| Q2 25 | 66.7% | 82.1% | ||
| Q1 25 | 63.4% | 84.8% | ||
| Q4 24 | 60.0% | 82.0% | ||
| Q3 24 | 60.7% | 80.0% | ||
| Q2 24 | 69.8% | 83.5% | ||
| Q1 24 | 64.6% | 86.8% |
营业利润率EMBCPATH
| Q4 25 | 31.9% | 3.2% | ||
| Q3 25 | 21.4% | -5.6% | ||
| Q2 25 | 31.8% | -4.6% | ||
| Q1 25 | 24.3% | 7.9% | ||
| Q4 24 | 11.0% | -12.2% | ||
| Q3 24 | 9.2% | -32.7% | ||
| Q2 24 | 20.5% | -14.8% | ||
| Q1 24 | 13.6% | 3.7% |
净利率EMBCPATH
| Q4 25 | 16.9% | 48.4% | ||
| Q3 25 | 10.0% | 0.4% | ||
| Q2 25 | 15.4% | -6.3% | ||
| Q1 25 | 9.1% | 12.2% | ||
| Q4 24 | — | -3.0% | ||
| Q3 24 | 5.1% | -27.2% | ||
| Q2 24 | 5.4% | -8.6% | ||
| Q1 24 | 10.1% | 8.4% |
每股收益（稀释后）EMBCPATH
| Q4 25 | $0.74 | $0.37 | ||
| Q3 25 | $0.44 | $0.00 | ||
| Q2 25 | $0.78 | $-0.04 | ||
| Q1 25 | $0.40 | $0.09 | ||
| Q4 24 | $0.00 | $-0.02 | ||
| Q3 24 | $0.24 | $-0.15 | ||
| Q2 24 | $0.25 | $-0.05 | ||
| Q1 24 | $0.50 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $201.3M | $1.4B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-613.1M | $1.9B |
| 总资产 | $1.1B | $2.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EMBCPATH
| Q4 25 | $201.3M | $1.4B | ||
| Q3 25 | $225.5M | $1.4B | ||
| Q2 25 | $230.6M | $1.6B | ||
| Q1 25 | $209.3M | $1.6B | ||
| Q4 24 | $210.0M | $1.6B | ||
| Q3 24 | $267.5M | $1.7B | ||
| Q2 24 | $275.1M | $1.9B | ||
| Q1 24 | $299.8M | $1.9B |
总债务EMBCPATH
| Q4 25 | — | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益EMBCPATH
| Q4 25 | $-613.1M | $1.9B | ||
| Q3 25 | $-650.6M | $1.7B | ||
| Q2 25 | $-669.6M | $1.7B | ||
| Q1 25 | $-736.2M | $1.8B | ||
| Q4 24 | $-768.8M | $1.7B | ||
| Q3 24 | $-738.3M | $1.8B | ||
| Q2 24 | $-763.7M | $2.0B | ||
| Q1 24 | $-769.6M | $2.0B |
总资产EMBCPATH
| Q4 25 | $1.1B | $2.9B | ||
| Q3 25 | $1.1B | $2.6B | ||
| Q2 25 | $1.2B | $2.6B | ||
| Q1 25 | $1.1B | $2.9B | ||
| Q4 24 | $1.1B | $2.7B | ||
| Q3 24 | $1.3B | $2.7B | ||
| Q2 24 | $1.3B | $2.8B | ||
| Q1 24 | $1.2B | $3.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.2M | $28.3M |
| 自由现金流经营现金流 - 资本支出 | $16.6M | $25.1M |
| 自由现金流率自由现金流/营收 | 6.4% | 6.1% |
| 资本支出强度资本支出/营收 | 0.2% | 0.8% |
| 现金转化率经营现金流/净利润 | 0.39× | 0.14× |
| 过去12个月自由现金流最近4个季度 | $205.8M | — |
8季度趋势，按日历期对齐
经营现金流EMBCPATH
| Q4 25 | $17.2M | $28.3M | ||
| Q3 25 | $84.0M | $41.6M | ||
| Q2 25 | $81.2M | $119.0M | ||
| Q1 25 | $31.8M | $146.1M | ||
| Q4 24 | $-5.3M | $28.1M | ||
| Q3 24 | $26.6M | $46.4M | ||
| Q2 24 | $-2.1M | $100.0M | ||
| Q1 24 | $24.3M | $145.6M |
自由现金流EMBCPATH
| Q4 25 | $16.6M | $25.1M | ||
| Q3 25 | $76.7M | — | ||
| Q2 25 | $80.8M | $106.2M | ||
| Q1 25 | $31.7M | $138.7M | ||
| Q4 24 | $-6.8M | $23.2M | ||
| Q3 24 | — | $45.0M | ||
| Q2 24 | $-11.8M | $98.8M | ||
| Q1 24 | $20.9M | $141.8M |
自由现金流率EMBCPATH
| Q4 25 | 6.4% | 6.1% | ||
| Q3 25 | 29.1% | — | ||
| Q2 25 | 27.3% | 29.8% | ||
| Q1 25 | 12.2% | 32.7% | ||
| Q4 24 | -2.6% | 6.5% | ||
| Q3 24 | — | 14.2% | ||
| Q2 24 | -4.3% | 29.5% | ||
| Q1 24 | 7.3% | 35.0% |
资本支出强度EMBCPATH
| Q4 25 | 0.2% | 0.8% | ||
| Q3 25 | 2.8% | 0.0% | ||
| Q2 25 | 0.1% | 3.6% | ||
| Q1 25 | 0.0% | 1.7% | ||
| Q4 24 | 0.6% | 1.4% | ||
| Q3 24 | 0.0% | 0.4% | ||
| Q2 24 | 3.6% | 0.4% | ||
| Q1 24 | 1.2% | 0.9% |
现金转化率EMBCPATH
| Q4 25 | 0.39× | 0.14× | ||
| Q3 25 | 3.18× | 26.25× | ||
| Q2 25 | 1.78× | — | ||
| Q1 25 | 1.35× | 2.82× | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.82× | — | ||
| Q2 24 | -0.14× | — | ||
| Q1 24 | 0.84× | 4.29× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EMBC
| Pen Needles | $185.5M | 71% |
| Safety | $37.3M | 14% |
| Syringes | $30.7M | 12% |
| Manufacturing Facility | $4.1M | 2% |
PATH
| Subscription Services | $247.6M | 60% |
| License | $150.0M | 36% |
| Professional Services And Other | $13.5M | 3% |
